

# A Human Glucocorticoid Receptor Gene Variant That Increases the Stability of the Glucocorticoid Receptor $\beta$ -isoform mRNA Is Associated with Rheumatoid Arthritis

ROEL H. DERIJK, MARCEL J.M. SCHAAF, GORDON TURNER, NICOLE A. DATSON, ERNO VREUGDENHIL, JOHN CIDLOWSKI, E. RONALD DE KLOET, PAUL EMERY, ESTHER M. STERNBERG, and SEVILLA D. DETERA-WADLEIGH

**ABSTRACT. Objective.** To study the occurrence and function of polymorphism in the human glucocorticoid receptor (hGR) gene in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

**Methods.** We used single stranded conformation polymorphism (SSCP) and direct sequencing to study the hGR gene in 30 patients with RA, 40 with SLE, and 24 controls. A newly identified polymorphism was transfected in COS-1 cells and the stability of the mRNA containing the polymorphism was tested using real-time PCR.

**Results.** A polymorphism in the hGR gene in exon9 $\beta$ , in an "ATTTA" motif, was found to be significantly associated with RA. Introduction of this polymorphism in the hGR $\beta$  mRNA was found to significantly increase stability *in vitro* compared to the wild-type sequence.

**Conclusion.** Our findings show an association between RA and a previously unreported polymorphism in the hGR gene. This polymorphism increased stability of hGR $\beta$  mRNA, which could contribute to an altered glucocorticoid sensitivity since the hGR $\beta$  is thought to function as an inhibitor of hGR $\alpha$  activity. (J Rheumatol 2001;28:2383–8)

## Key Indexing Terms:

RHEUMATOID ARTHRITIS  
GLUCOCORTICOID RECEPTOR

SYSTEMIC LUPUS ERYTHEMATOSUS  
ATTTA MOTIF

Glucocorticoids are widely used in the management of chronic inflammatory diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)<sup>1,2</sup>. However, in clinical practice pharmacological dosages are needed, suggesting glucocorticoid resistance of the target tissue<sup>3,4</sup>. In

addition, several studies have suggested that this glucocorticoid resistance could play an important role in the clinical management of RA and SLE<sup>4,9</sup>.

Glucocorticoids exert their effect by binding to an intracellular receptor, the glucocorticoid receptor- $\alpha$  (GR $\alpha$ ). The GR-ligand complex translocates to the nucleus where it interacts with glucocorticoid responsive elements (GRE) in promoter regions of target genes, altering their expression. GR $\alpha$  has been shown to interact with other transcription factors, such as AP-1 and NF- $\kappa$ B, thereby inhibiting their activity. The interaction with NF- $\kappa$ B appears to play a central role in the immunosuppressive action of glucocorticoids<sup>10</sup>. The human GR gene (hGR) consists of 10 exons, of which exons 1–9 $\alpha$  are transcribed into hGR $\alpha$  mRNA, which is translated into a functional receptor, hGR $\alpha$ . Alternative splicing of the primary transcript results in an mRNA containing exons 1–9 $\beta$ , which results in the expression of the alternate product, the hGR $\beta$ <sup>11–13</sup>. The hGR $\beta$  does not bind hormone and is transcriptionally inactive. *In vitro* studies have shown that hGR $\beta$  can act as a dominant negative inhibitor of hGR $\alpha$  activity, by a mechanism that is largely unknown<sup>14,15</sup>. However, since several laboratories have not been able to reproduce this result<sup>16,17</sup>, this inhibiting activity is still under debate<sup>18</sup>.

Changes in expression of GR have been reported<sup>5,8</sup>,

---

From the Rijngroep, Oegstgeest; Medical Pharmacology, Leiden University, Leiden, The Netherlands; Laboratory of Signal Transduction, NIEHS, NIH, Research Triangle Park, North Carolina, USA; University of Leeds, Leeds, UK; Section on Neuroendocrine Immunology and Behavior, Neural Immune Program, NIMH, NIH; and Unit of Gene Mapping and Expression, Clinical Neurogenetic Branch, NIMH, NIH, Bethesda, Maryland, USA.

Supported by a personal grant to Dr. R.H. De Rijk by the Dutch Rheumatoid Fund.

R.H. DeRijk, Dr, Rijngroep, Medical Pharmacology, Leiden University; N.A. Datson, Dr; E. Vreugdenhil, Dr; E.R. de Kloet, Prof. Dr., Medical Pharmacology, Leiden University; M.J.M. SchAAF, Dr; J. Cidlowski, PhD, Laboratory of Signal Transduction, NIEHS, NIH; P. Emery, MD, PhD, ARC Professor of Rheumatology, University of Leeds; E.M. Sternberg, MD, PhD, Section on Neuroendocrine Immunology and Behavior, Director, Neural Immune Program, NIMH, NIH; S.D. Detera-Wadleigh, PhD; G. Turner, BSc, Unit of Gene Mapping and Expression, Clinical Neurogenetic Branch, NIMH, NIH.

Address reprint requests to Dr. R.H. DeRijk, Rijngroep, Endegeesterstraatweg 5, 2342 AJ Oegstgeest, The Netherlands. E-mail: rderijk@rijngroep.nl

Submitted March 1, 2001; revision accepted May 31, 2001.

while in SLE the amount of hGR was found to correlate with glucocorticoid sensitivity and therapy efficacy<sup>6</sup>. Several polymorphisms in the hGR gene have been shown to be associated with overt glucocorticoid resistance<sup>19-22</sup>. However, no studies have been conducted to investigate whether any GR variant confers genetic risk for rheumatic diseases.

To determine whether hGR gene variants contribute to susceptibility to RA or SLE, we screened all exons and splice boundaries for variants in a panel of patients with RA and SLE and conducted association tests using a case-control paradigm. We report a possible association with RA and a hGR gene variant that confers stability to the transcript encoding the hGR $\beta$  isoform.

## MATERIALS AND METHODS

**Patient and control DNA samples.** Thirty RA patients and 40 SLE patients were recruited from the outpatient department of Sellyoak Hospital and Queen Elizabeth Hospital in the United Kingdom by Dr. Emery. The 40 patients with SLE consisted of 39 women and one man. Patients with RA or SLE according to American College of Rheumatology criteria for moderate to severe disease were selected randomly from those attending a routine secondary care clinic. Blood samples were drawn with informed consent and genomic DNA was isolated using peripheral blood mononuclear cells, which were separated by density gradient centrifugation, and total polymerase chain reaction grade cellular DNA was prepared by sodium dodecyl sulfate-Nonidet-Tween 20 treatment followed by proteinase K digestion, boiling, and phenol-chloroform extraction. DNA was stored in aliquots at  $-20^{\circ}\text{C}$  at an approximate concentration of 20 ng/ml.

Control DNA was obtained from donor blood from a group of 24 healthy volunteers from an anonymous DNA collection of North British Caucasians with no personal or family history of chronic autoimmune, metabolic, or infectious disease. Due to the source of blood donor groups as controls there is a bias towards male sex (about two-thirds male). For ethical reasons no other identifier information was available on these subjects.

**Polymerase chain reaction-single stranded conformation polymorphism (PCR-SSCP).** To screen the hGR gene for variants we employed SSCP analysis followed by sequencing<sup>23</sup>. Primer pairs were designed to span the hGR exons and intron sequences flanking the splicing sites presented previously<sup>12</sup>. In general, the size of the PCR products was kept to a maximum of 250 bp. Below are the primers associated with the polymorphism in exon 9 $\beta$ .

9 $\beta$ N5: 5' AGT GTC TTT TTA CCT ACG CA 3'

9 $\beta$ O3: 5' ATG TTT CTC CAT ATT TGG CA 3'

The oligomers were purchased from BioServe Biotechnologies (Gaithersburg, MD, USA). Between 30 and 40 ng of genomic DNA was used as template for each PCR. PCR I buffer from Perkin-Elmer-Cetus and a mixture of 4 dNTP in a final concentration of 200  $\mu\text{M}$  each were used. PCR amplification was done in a Perkin-Elmer PE GeneAmp 9600 thermocycler using the following conditions: initial denaturation at  $95^{\circ}\text{C}$  for 5 min, 30 cycles of denaturation at  $94^{\circ}\text{C}$  for 30 s, annealing at  $55^{\circ}\text{C}$  for 30 s, and extensions at  $72^{\circ}\text{C}$  for 1 min followed by a final extension at  $72^{\circ}\text{C}$  for 10 min. An aliquot of each amplicon was used as a template in the second PCR that was performed in the same manner except for the presence of  $\alpha^{32}\text{P}$ -dCTP (ICI Biochemicals) and a lower concentration of dCTP (0.2  $\mu\text{M}$ ). Sequence loading buffer was added to each PCR product and denaturation was conducted at  $95^{\circ}\text{C}$  for 5 min. After cooling on ice, aliquots of the denatured amplicons were applied to 6% nondenaturing MDE gels in  $0.5 \times \text{TBE}$  buffer. Electrophoresis was performed either in the cold room ( $4^{\circ}\text{C}$ ) or at room temperature. Autoradiography was done for a minimum of roughly 1 hour.

**Cycle sequencing.** Prior to cycle sequencing, the PCR amplicons were purified using Sephadex G-25 spin columns. Cycle sequencing reactions were done either in the presence of the  $\alpha^{32}\text{P}$ -dATP (ICI Biochemicals) for manual electrophoresis or by using the dye terminator method for automated sequencing with either the ABI 373 or 377 sequencer. PCR conditions were as described in the previous section.

**Cell culture, transfection, and actinomycin-D treatment.** COS-1 cells were grown as described<sup>24</sup>. Subconfluent monolayers were transfected, using TransIt reagent (PanVera, USA). After 5 h incubation with the TransIt reagent/DNA mixture, cells were re-fed with supplemented Dulbecco's modified Eagle's medium.

Cells were transfected with either the hGR $\beta$  expression vector pCMVhGR $\beta$  or the mutated version of this vector, pCMVhGR $\beta$ mut. This mutated vector was obtained by site-directed mutagenesis of pCMVhGR $\beta$ , using the QuikChange kit (Stratagene, Palo Alto, CA, USA) according to the manufacturer's instructions. At position 3736 in the hGR $\beta$  cDNA, an A was replaced by a G (primers used: GTGTGAAATGTTAACTTTT-TATTTTTTCCTTTAAATTTGCTGTTCTGG and CCAGAACAGC-AAATTTAAAGGAAAAATAAAAGTTAAACATTTCCACAC).

Twenty-four hours after the transfection, cells from each transfection were transferred and distributed over 3 smaller wells (one well for each time point to be taken). Twenty-four hours later, actinomycin-D was added to the medium (1  $\mu\text{g}/\text{ml}$ ). At 0, 3, and 6 h after addition of actinomycin-D, total RNA was isolated using Trizol reagent (Life Technologies Gibco BRL), according to the manufacturer's instructions. RNA was DNase-treated (DNase purchased from Promega) and after 2 phenol/chloroform extractions stored at  $-20^{\circ}\text{C}$ .

**Real-time PCR.** To quantitate hGR $\beta$  mRNA levels, real-time RT-PCR was performed, using the TaqMan Gold RT-PCR kit (PE Applied Biosystems). About 50 ng of total RNA was added to 49  $\mu\text{l}$  of  $1 \times \text{TaqMan}$  buffer A, 10 mM  $\text{MgCl}_2$ , 300  $\mu\text{M}$  dATP, dCTP, dGTP, 600  $\mu\text{M}$  dUTP, 10  $\mu\text{M}$  GR $\beta$  forward primer GCT-GGA-TAA-TTA-GCA-TGG-GAT-G, 10  $\mu\text{M}$  GR $\beta$  reverse primer AAT-TGC-TCC-CTG-CCT-CTG-A, 5  $\mu\text{M}$  GR $\beta$  probe ATG-AAG-GAA-AGC-CAC-GCT-CCC-T, 0.05 U/ $\mu\text{l}$  AmpliTaq Gold DNA polymerase, 0.25 U/ $\mu\text{l}$  MultiScribe Reverse Transcriptase, and 0.4 U/ $\mu\text{l}$  RNase inhibitor. Reactions were run on an ABI Prism 7700 sequence detection system (PE Applied Biosystems). Reverse transcription was performed for 30 min at  $48^{\circ}\text{C}$ , then the sample was incubated 10 min at  $95^{\circ}\text{C}$  and 40 cycles of PCR were performed (15 s at  $95^{\circ}\text{C}$  and 1 min at  $60^{\circ}\text{C}$ ). As a standard, the ribosomal RNA (rRNA) content was measured for each sample in a separate reaction, using the rRNA TaqMan PCR kit according to the manufacturer's instructions. For both hGR $\beta$  mRNA and rRNA, relative standard curves were obtained by making serial dilutions of a control sample. Using these curves, the relative amount of hGR $\beta$  mRNA was measured in each sample, and divided by the relative amount of rRNA measured in that sample. Subsequently, levels were normalized to the  $t = 0$  level. Experiments were performed in duplicate. Data shown are means of 3 separate experiments ( $n = 3$ ).

**Statistical analysis.** Statistical significance of the occurrence of a certain polymorphism was tested using chi-square statistics provided by the SPSS+ statistical package. Compared were: RA versus controls, SLE versus controls, and RA versus SLE patients. The Hardy-Weinberg equilibrium was also tested with chi-square statistics.

hGR $\beta$  mRNA levels at 3 and 6 h after actinomycin-D addition were analyzed by analysis of variance (ANOVA). Post-hoc comparisons were done by Tukey's t test. Statistical significance was accepted at  $p < 0.05$ .

## RESULTS

**Variants in hGR exon 9 $\beta$  and association studies with RA and SLE.** A previously unreported polymorphism in the 3' untranslated region (UTR) located at the end of exon 9 $\beta$  was detected at position 3669. Figure 1 shows the SSCP pattern

for unrelated patients with either RA or SLE, and Table 1 indicates the allele frequencies of this polymorphism.

As indicated there are 4 possible bands (1–4, Figure 1). For example, SLE Patient 22 (Figure 1B), showed 3 bands (1–3). Some SLE patients, for example Patient 9, displayed band 4, the fastest migrating band. Samples 8 and 26 did not display band 2. Sequencing of the PCR amplimers of SLE Patients 8, 9, 22, and 30 indicated a nucleotide transition “A” to “G” in the “ATTTA” sequence, giving rise to a “GTTTA” sequence in Patients 8, 9, and 30 (Figure 1C). SLE Patient 22 displayed the wild-type “A” and SLE Patient 8 was homozygous for the “G” allele, while Patients 9 and 30 were heterozygotes (note the faint band 2 in Figure 1B). We found 12 out of 40 patients with SLE were carriers of the polymorphism (Patients 2, 3, 8, 9, 13, 15, 17, 26, 30, 32, 37, and 39). Moreover, 2 SLE patients (8 and 26) were homozygotes.

We scored the genotypes of the RA patients based on knowledge of the sequences that correspond to specific SSCP banding patterns (Figure 1A). For example, RA Patient 15 displayed a banding pattern that was identical to SLE Patient 22; therefore it should have the wild-type sequence. RA Patient 27 had the identical banding pattern as SLE Patient 9, i.e., heterozygote. RA Patient 30 gave the same banding pattern as SLE Patients 8 and 26. We concluded that 10 RA patients (3, 4, 5, 8, 9, 12, 19, 20, 27, 29) were heterozygotes. Only one RA patient (30), missing the second band (Figure 1B), was designated homozygote for this polymorphism. When tested separately, controls, and patients with SLE and RA are, for this mutation, in Hardy-Weinberg equilibrium.

Direct sequencing of DNA samples from 24 healthy control individuals, using the PE-ABI377 system, revealed that only 3 of these 24 controls were heterozygote carriers of the polymorphism (data not shown).

The allele frequencies in controls and RA and SLE patients are shown in Table 1. Subsequent chi-square statistics indicate significant differences in the frequency of

occurrence of this polymorphism in RA patients and controls. Thus, the Pearson chi-square of 4.2,  $p < 0.035$ , between RA patients versus controls was significant, while between SLE patients and controls the Pearson chi-square of 3.3,  $p = 0.057$ , was not significant. There was no significant difference in allele frequencies between patients with RA and SLE.

*Effect of polymorphism on hGR $\beta$  mRNA stability.* To determine whether the nucleotide substitution exerted an effect on the stability of the hGR $\beta$  transcript, a mutated version of an hGR $\beta$  expression vector was prepared by site-directed mutagenesis. The mutated version and the wild-type hGR $\beta$  expression plasmids were transfected into COS-1 cells. Actinomycin-D was added and 0, 3, and 6 h later, cells were harvested and total RNA was isolated. Quantitation of mRNA levels was by real-time PCR (Figure 2). ANOVA revealed a stabilizing effect of the mutation at 3 and 6 h [ $F(1,1) = 5.32$ ,  $p < 0.05$ ] on the mRNA, as revealed by the increased half-life. Post-hoc comparison showed a significant difference between the wild-type hGR $\beta$  and the mutant at 3 h ( $p < 0.05$ ).

## DISCUSSION


Based on the importance of glucocorticoid therapy and the frequent occurrence of glucocorticoid resistance in rheumatoid diseases, we investigated the association between polymorphisms in the hGR gene and RA and SLE. We found an association between a previously unreported A to G transition in exon9 $\beta$  of the hGR gene in patients with RA. The transition was observed in an “ATTTA motif” that was located in a region encoding the 3’ UTR of hGR $\beta$  mRNA, and was found to confer stability to the mRNA.

The pathogenesis of both RA and SLE is not well understood, but a pronounced difference in concordance rates between monozygotic and dizygotic twins, as well as linkage and segregation animal studies, provides strong evidence for the role of genetic factors<sup>25,26</sup>. Among the many loci identified to have a possible association with SLE or RA<sup>25</sup>, one report described a susceptibility locus for RA in the 5q32–33 region<sup>27</sup>, which is in close proximity to the hGR gene thought to be located at 5q31<sup>28</sup>. The association of the A to G transition in exon 9 $\beta$  of the hGR gene with RA would be consistent with the presence of a susceptibility locus at or near the hGR gene region. Our results showing no significant association of the A to G transition in SLE are also consistent with the lack of linkage in SLE with the hGR gene<sup>29</sup>.

In addition to the polymorphism in exon 9 $\beta$ , a silent mutation [AAT (Asn) to AAC (Asn)] in the coding region of exon 9 $\alpha$  was found to occur in about 25% of the seemingly healthy population<sup>30</sup>. We detected this polymorphism at a similar frequency in RA and SLE patients and in controls (range 27.5–36%, data not shown), and no statistically significant differences between groups were found. Thus

*Table 1.* Frequencies of polymorphism in the “ATTTA motif” at position 3736 in exon 9 $\beta$ . The table shows the gene type and allele frequencies of the hGR $\beta$  polymorphism in SLE and RA patients and controls. Two gene types exist, the wild-type A and the G polymorphism at the first position in the ATTTA sequence. Accordingly, wild-types (AA), heterozygotes (AG), and homozygotes (GG) were identified using SSCP and sequencing, (Figure 1). In addition, allele frequencies were calculated and, using chi-square testing, we observed a significant difference in allele frequencies between RA patients and controls ( $p = 0.035$ ), but not between SLE patients and controls ( $p = 0.057$ ) or between RA and SLE patients.

Patients	Gene Type			Allele Frequencies		p
	AA	AG	GG	A	G	
SLE (n = 40)	28	10	2	0.82	0.18	0.057
RA (n = 30)	19	10	1	0.8	0.2	0.035
Control (n = 24)	21	3	0	0.94	0.06	



*Figure 1.* Polymorphism in the “ATTTA motif” in exon 9 $\beta$  revealed by SSCP gels and sequencing. PCR products of 30 patients with RA and 40 with SLE were run on SSCP gels, which revealed a shift in bands in 11 RA patients (panel A) and 12 SLE patients (panel B). Four SLE patients (Patients 8, 9, 22, 30) were further analyzed by direct sequencing (panel C). Direct sequencing showed that SLE Patient 8 is homozygous for the polymorphism and showed a transition from “ATTTA” to “GTTTA,” as indicated. SLE Patients 9 and 30 have both bands (Figure 1C), an “A” and “G” at this position and are therefore characterized as heterozygotes. In contrast, SLE Patient 22 shows the wild-type sequence. Based on these data, we characterized 12 patients with SLE as carriers of the polymorphism, while Patients 8 and 26 are probably homozygotes. Since the SSCP pattern of patients with RA was almost completely identical to the SLE SSCP gel, we designated 11 of the 30 patients with RA (Patients 3, 4, 5, 8, 9, 12, 19, 20, 27, 29, 30) as carriers of the GTTTA polymorphism. Only RA Patient 30 seems to be a homozygote (band 2 is missing).




Figure 2. GR $\beta$  mRNA levels after actinomycin-D treatment. COS-1 cells were transfected with the expression plasmid pCMVGR $\beta$  (■), or vector pCM $\beta$ mut, which contains a mutated “ATTTA motif” (to “GTTTA”) in the 3’ UTR (●). At 3 and 6 h after actinomycin-D treatment, the cells transfected with pCMVGR $\beta$  show a significantly ( $p < 0.05$ ) larger decrease in GR $\beta$  mRNA levels than the cells transfected with the mutated vector. Data are expressed as mean ( $n = 3$ )  $\pm$  SEM.

while this second polymorphism seems to occur at high frequency in several different populations, the transition polymorphism appears to be more selectively expressed in patients with RA. Confirmation of this finding in larger samples would be warranted.

AUUUA pentamers are often found in A/U-rich elements (ARE) in the 3’ UTR of mRNA that code for protooncogenes, nuclear transcription factors, and cytokines and can function as regulators of mRNA stability. In most cases, its presence destabilizes mRNA<sup>31,32</sup>, but under certain conditions stabilization has been observed<sup>33</sup>. Most likely it represents a binding site for specific proteins. A mutation of an AUUUA sequence has been shown to increase the half-life of *c-fos*<sup>34</sup> and interleukin 3<sup>35</sup> mRNA. The 3’ UTR of hGR $\beta$  mRNA contains 2 tandems, at positions 2561 and 2597 and at 3669 and 3736<sup>11</sup>, which are both located in an ARE. The ARE does not contain overlapping UUAUUUAU nonamers, which means they are classified as class I AUUUA containing ARE<sup>32</sup>, like the ARE that are found in the 3’ UTR of *c-fos*, *c-jun*, and *c-myc* mRNA<sup>36</sup>. Mutation of the pentamer at position 3669 (the mutation associated with RA, this study) resulted in an increased stability of the hGR $\beta$  mRNA *in vitro*. Therefore, we conclude that turnover of hGR $\beta$  mRNA is dependent on the presence of this AUUUA motif in the 3’ UTR, and that the described transition results in an increased stability of this messenger *in vivo*.

While the functional implications of this polymorphism

*in vivo* in RA are not known and require further study, previous functional investigations have indicated abnormalities in hypothalamic-pituitary-adrenal activity in which alterations in glucocorticoid sensitivity or feedback could potentially play a role<sup>37-39</sup>.

In asthma, another chronic inflammatory disease, glucocorticoid resistance was found to be associated with elevated expression of the hGR $\beta$ <sup>40,41</sup>. In addition, recently it has been shown that glucocorticoid treatment of asthma patients decreased expression of hGR $\alpha$  but not hGR $\beta$  in skin biopsies, as revealed by immunocytochemistry, thereby decreasing the GR $\alpha$ /GR $\beta$  ratio<sup>40</sup>. It has been demonstrated *in vitro* that such a decrease in the GR $\alpha$ /GR $\beta$  ratio results in decreased hGR $\alpha$  induced transactivation on a GRE driven promoter<sup>13,14</sup>. Therefore it has been suggested that a shift in the GR $\alpha$ /GR $\beta$  ratio could be responsible for the often observed glucocorticoid resistance that develops in asthma after prolonged treatment<sup>40</sup>. The data we report here, showing a mutation in RA patients of an “AUUUA motif” that *in vitro* is associated with enhanced stability of the hGR $\beta$ , could result in increased expression of hGR $\beta$  and consequently in glucocorticoid resistance in RA patients carrying this polymorphism.

In summary, we describe for the first time a possible association in RA patients with a previously unknown polymorphism in the hGR gene. This “ATTTA” to “GTTTA” transition was found to result in increased stability of hGR $\beta$  mRNA when tested *in vitro*. We suggest that this polymorphism could contribute to changes in glucocorticoid resistance by means of attenuation of hGR efficacy. It remains to be shown if this polymorphism can be viewed as a susceptibility factor in the pathogenesis of RA.

#### ACKNOWLEDGMENT

The skilful technical reproduction of the films by Ton Huygen is greatly appreciated. We thank Prof. Dr. H. van Houwelingen for the determination of the Hardy-Weinberg statistics and Francesco S. di Giovine, MD, PhD, for providing control DNA samples.

#### REFERENCES

- Morand EF. Corticosteroids in the treatment of rheumatologic diseases. *Curr Opin Rheumatol* 2000;12:171-7.
- Weiss MM. Corticosteroids in rheumatoid arthritis. *Semin Arthritis Rheum* 1989;19:9-21.
- Wilckens T. Glucocorticoids and immune function: physiological relevance and pathogenic potential of hormonal dysfunction. *Trends Pharmacol Sci* 1995;16:193-7.
- Derijk RH, Sternberg EM. Corticosteroid-resistance and disease. *Ann Med* 1997;29:79-82.
- Schlaghecke R, Kornely E, Wollenhaupt J, Specker C. Glucocorticoid receptors in rheumatoid arthritis. *Arthritis Rheum* 1992;35:740-4.
- Tanaka H, Akama H, Ichikawa Y, Makino I, Homma M. Glucocorticoid receptor in patients with lupus nephritis: relationship between receptor levels in mononuclear leukocytes and effect of glucocorticoid therapy. *J Rheumatol* 1992;19:878-83.
- Harbuz MS, Jessop DS. Is there a defect in cortisol production in rheumatoid arthritis? *Rheumatology* 1999;38:298-302.

8. Sanden S, Tripmacher R, Weltrich R, et al. Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases. *J Rheumatol* 2000;27:1265-70.
9. Seki M, Ushiyama C, Seta N, et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to their therapeutic efficacy in patients with systemic lupus erythematosus. *Arthritis Rheum* 1998;41:823-30.
10. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor- $\kappa$ B and steroid receptor-signaling pathways. *Endocrin Rev* 1999;20:435-59.
11. Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional glucocorticoid receptor cDNA. *Nature* 1985;318:635-41.
12. Encio IJ, Detera-Wadleigh S. The genomic structure of the human glucocorticoid receptor. *J Biol Chem* 1991;266:7182-8.
13. Oakley RH, Sar M, Cidlowski JA. The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. *J Biol Chem* 1996;271:9550-9.
14. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. *J Clin Invest* 1995;95:2435-41.
15. Oakley RH, Jewell CM, Yudit MR, Bofetiado DM, Cidlowski JA. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. *J Biol Chem* 1999;39:27857-66.
16. Hecht K, Carlstedt-Duke J, Stiernas P, Gustafson J-A, Bronnegard M, Wikstrom A-C. Evidence that the  $\beta$ -isoform of the human glucocorticoid receptor does not act as a physiological significant repressor. *J Biol Chem* 1997;272:26659-64.
17. de Lange P, Koper JW, Brinkmann AO, de Jong FH, Lamberts SW. Natural variants of the beta isoform of the human glucocorticoid receptor do not alter sensitivity to glucocorticoids. *Mol Cell Endocrinol* 1999;153:163-8.
18. Vottero A, Chrousos GP, Carlstedt-Duke J. GR $\beta$ : two views. *Trends Endocrinol Metab* 1999;10:333-42.
19. Hurlley DM, Accili D, Stratakis CA, et al. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. *J Clin Invest* 1991;87:680-6.
20. Panarelli M, Holloway CD, Fraser R, et al. Glucocorticoid receptor polymorphism, skin vasoconstriction and other metabolic intermediate phenotypes in normal subjects. *J Clin Endocrinol Metab* 1998;83:1846-52.
21. Karl M, Lamberts SW, Detera-Wadleigh S, et al. Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. *J Clin Endocrinol Metab* 1993;76:683-9.
22. Lamberts SW, Huizenga NATM, de Lange P, de Jong FH, Koper JW. Clinical aspects of glucocorticoid sensitivity. *Steroids* 1996;61:157-60.
23. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphism using the polymerase chain reaction. *Genomics* 1989;5:874-9.
24. Allgood V, Powell-Oliver F, Cidlowski JA. Vitamin B6 influences glucocorticoid dependent gene-expression. *J Biol Chem* 1990;265:12424-33.
25. Criswell LA, Amos CI. Update on genetic risk factors for systemic lupus erythematosus and rheumatoid arthritis. *Curr Opin Rheumatol* 2000;12:85-90.
26. Remmers EF, Longman RE, Du Y, et al. A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. *Nature Genet* 1996;14:82-5.
27. Cornelis F, Faure S, Martinez M, et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. *Proc Natl Acad Sci USA* 1998;95:10746-50.
28. Theriault A, Boyd E, Harrap SB, Hollenberg SM, Conner JM. Regional chromosomal assignment of the human glucocorticoid receptor gene to 5q31. *Hum Genet* 1989;83:289-91.
29. Wakeland EK, Wandstrat AE, Liu K, Morel L. Genetic dissection of systemic lupus erythematosus. *Curr Opin Immunol* 2001;11:701-7.
30. Koper JW, Stolk RP, de Lange P, et al. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. *Hum Genet* 1997;99:663-8.
31. Shaw G, Kamilaris T. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. *Cell* 1986;46:659-67.
32. Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. *Trends Biochem Sci* 1995;20:465-70.
33. Ruth JH, Esnault S, Jarzembowski JA, Malter JS. Calcium ionophore upregulation of AUUUA-specific binding protein activity is contemporaneous with granulocyte macrophage colony-stimulating factor messenger RNA stabilization in AML14.3D10 cells. *Am J Respir Cell Mol Biol* 1999;21:621-8.
34. Shyu AB, Belasco JG, Greenberg ME. Two distinct destabilizing elements in the c-fos message trigger deadenylation as a first step in rapid mRNA decay. *Genes Dev* 1991;5:221-31.
35. Stoecklin G, Hahn S, Moroni C. Functional hierarchy of AUUUA motifs in mediating rapid interleukin-3 mRNA decay. *J Biol Chem* 1994;269:28591-7.
36. Chen CY, Shyu AB. Selective degradation of early-response-gene mRNAs: functional analysis of sequence features of the AU-rich elements. *Mol Cell Biol* 1994;14:8471-82.
37. Neeck G, Federlin K, Graef V, Rusch D, Schmidt KL. Adrenal secretion of cortisol in patients with rheumatoid arthritis. *J Rheumatol* 1990;17:24-9.
38. Chikanza LC, Petoru P, Kinsley G, Chrousos GP, Panayi GS. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. *Arthritis Rheum* 1992;35:1281-8.
39. Cash JM, Crofford LJ, Galucci WT, et al. Pituitary-adrenal axis responsiveness to ovine corticotropin releasing hormone in patients with rheumatoid arthritis treated with low dose prednisone. *J Rheumatol* 1992;19:1692-6.
40. Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor  $\beta$ -isoform. *J Allergy Clin Immunol* 2000;105:943-50.
41. Leung DY, Hamid Q, Vottero A, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor  $\beta$ . *J Exp Med* 1997;186:1567-74.